Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft safety review: the rodent thyroid C-cell signal and its… — submissions

The 16 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-019/2
Series
Public comment period
Version
1.0
Published
13 Jun 2025
Last reviewed
13 Jun 2025
Next review
13 Jun 2026
Identifier
10.71829/cei.cp.19
Certainty
Not rated
Cycle
2025 Q2
Window
20 Apr 2025 – 20 May 2025
Status
Closed
Submissions
16

§2Submissions and responses

16 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Frideswide Grünbaum-Sowande, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-THYROID-C-CE/006 received 21 Apr 2025

Risk-of-bias judgements are reported as an overall rating without the domains

The draft reports a single overall risk-of-bias judgement per study. The respondent states that the overall judgement conceals which domain drove it, and that a reader assessing whether the concern applies to their question needs the domain.

The respondent proposes a domain-level table with the supporting quotation for each judgement.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted01 Jun 2025

The secretariat accepts this submission. The overall judgement is a summary of the domains and publishing only the summary makes it uncheckable.

Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.

Dr Delphine Ravensworth, MD, PhD, FESC ISO/IEC 17025-accredited contract testing laboratory
DRAFT-THYROID-C-CE/005 received 24 Apr 2025

References should carry a persistent identifier for every cited source

Several references in the draft carry a journal, a year and a volume but no persistent identifier. The respondent, who works in a library setting, states that retrieval of such a reference is materially slower and that identifiers should be supplied throughout.

The respondent asks in the alternative that where an identifier exists but is not carried, the omission be explained rather than left as a gap the reader must interpret.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted in part02 Jun 2025

The secretariat accepts the second limb of this submission and declines the first. Identifiers are supplied wherever the Institute holds one. Where the Institute does not hold an identifier it will not supply one, because a reconstructed identifier that resolves to the wrong record is a worse defect than an absent one.

Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.

Dr Quentin Zimmerthal, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-THYROID-C-CE/010 received 29 Apr 2025

A surrogate outcome is used as the anchor without validation evidence

The anchor outcome in the draft is a surrogate. The respondent states that the relationship between the surrogate and the outcome a decision turns on is itself an evidential question, and that the draft assumes it.

The respondent proposes that no surrogate serve as an anchor.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part08 Jun 2025

The secretariat accepts this submission in part. The anchor is retained where the surrogate is the only outcome the contributing trials measured, and the validation question is addressed rather than assumed.

Where the anchor is a surrogate, the synthesis now states the evidence for the surrogate relationship, rates it separately, and downgrades the anchor rating for indirectness accordingly rather than carrying the surrogate as though it were the outcome of interest.

Dr Emiliana Ollerenshaw, MD, FRCS Academic peptide-chemistry group
DRAFT-THYROID-C-CE/011 received 29 Apr 2025

Point estimates are given without an interval

Several estimates in the draft appear as single figures. The respondent states that a point estimate without an interval invites a precision the underlying data do not support, and that the effect is worst where the estimate is drawn from a small contributing set.

The respondent proposes that no point estimate appear anywhere in the document set without its interval, including in summary tables and in the abstract.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted in part11 Jun 2025

The secretariat accepts this submission in part. Intervals are added wherever the source reports one. The proposal is declined for figures the source published without an interval, because the Institute will not compute an interval a source did not report.

Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.

Dr Abimbola Sotomayor-Ekwueme, PharmD, PhD Reader in Pharmaceutics
DRAFT-THYROID-C-CE/003 received 30 Apr 2025

An indirect comparison is presented without an assessment of transitivity

The draft compares two interventions through a common comparator. The respondent states that the trials contributing to each side differ in background therapy and in baseline severity, and that the resulting estimate assumes a similarity the draft does not test.

The respondent proposes that transitivity be assessed explicitly and reported before any indirect estimate is presented.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted15 Jun 2025

The secretariat accepts this submission. An indirect estimate presented without a transitivity assessment invites a reader to treat an assumption as a result.

Transitivity is now assessed against a stated list of effect modifiers and reported before any indirect estimate, and where the assessment fails the contrast is reported as unestimable with the reason rather than estimated with a caveat.

Dr Lorcan Whitmarsh-Obi, MSc (Regulatory Affairs) Public-sector clinical trials unit
DRAFT-THYROID-C-CE/016 received 01 May 2025

The search strategy as published cannot be re-run

The strategy is described in prose rather than reproduced as executed. The respondent, an information specialist, attempted to reconstruct it and obtained a different yield, which may reflect the reconstruction or the original.

The respondent proposes that the strategy be published line by line as run in each database, with the interface, the date and the number of records retrieved at each line.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted03 Jun 2025

The secretariat accepts this submission. A strategy that cannot be re-run cannot be checked, and a review whose search cannot be checked rests on an assertion.

The full line-by-line strategy for each database is now published with the interface, the run date and the yield at each line, and the total retrieved is reconciled against the screening flow.

Brigitta Grünbaum-Sowande, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-THYROID-C-CE/009 received 03 May 2025

Analytical surveys are treated as evidence about suppliers when they establish only what was in a sample

Several included surveys purchased material anonymously and analysed it. The respondent states that where the chain from a named supplier to the analysed vial cannot be documented, the result describes a sample and not a supplier.

The respondent proposes that provenance be an explicit eligibility dimension, with surveys reported separately according to whether it could be established.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted07 Jun 2025

The secretariat accepts this submission. Moderate certainty evidence from the included surveys supports statements about material circulating in a market; it does not support statements about any named supplier's output.

Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a sample-level result.

Dr Ulysses Bellingham-Ojo, PharmD, MSc National medicines information service · industry submission
DRAFT-THYROID-C-CE/004 received 04 May 2025

A sponsor trial meeting the eligibility criteria was excluded

The submission is made on behalf of the sponsor. It identifies a completed trial of the sponsor's compound that meets the stated eligibility criteria and does not appear in the included set, and supplies the trial report and the registry record.

The sponsor asks that the trial be included and the estimate recomputed. No view is expressed on the direction the recomputation should take.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part02 Jun 2025

The secretariat accepts this submission in part. The trial does meet the criteria and has been included. The recomputed estimate is materially unchanged, which the response states explicitly so that the outcome of the correction is on the record.

The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified as an industry submission.

Dr Wojciech Kaltenbach-Mensah, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-THYROID-C-CE/001 received 06 May 2025

Results at materially different follow-up durations are pooled

Contributing trials report the outcome at durations ranging across more than a year. The draft pools them into a single estimate. The respondent states that a mean at one duration and a mean at another are not estimates of the same quantity when the effect is still changing.

The respondent proposes that estimates be reported by duration band.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted11 Jun 2025

The secretariat accepts this submission. Pooling across durations assumes a plateau the contributing trials do not demonstrate.

Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.

Dr Séverine Oduya-Kaltenbrunner, PhD Head of Mass Spectrometry, academic core facility
DRAFT-THYROID-C-CE/013 received 08 May 2025

A funnel plot is presented for a set too small to interpret it

The draft includes a funnel plot for an outcome contributed by fewer than ten studies. The respondent states that asymmetry cannot be assessed reliably at that number and that presenting the plot invites a conclusion the data cannot support.

The respondent proposes that the plot be removed and replaced with a statement that publication bias could not be assessed.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseAccepted02 Jun 2025

The secretariat accepts this submission. Presenting an uninterpretable graphic is not a neutral act.

The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.

Dr Wolfram Tollemache, PhD (Toxicology) Health-technology assessment agency
DRAFT-THYROID-C-CE/002 received 10 May 2025

Two included studies do not meet the registered eligibility criteria

The respondent identifies two studies in the included set whose duration falls below the minimum stated in the protocol, and one excluded study that appears to meet every criterion.

The respondent proposes that the three be reassessed and that the outcome of the reassessment be recorded whichever way it goes.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted in part28 May 2025

The secretariat accepts this submission in part. On reassessment, one of the two included studies does fall below the minimum duration and has been removed. The second reports a duration that met the criterion in the protocol version registered at the time. The excluded study was excluded for a reason not clearly recorded, which was a documentation failure.

One study has been removed from the included set and the estimate recomputed, the exclusion reason for the third study has been corrected in the excluded-studies table, and the screening decisions are now recorded against the protocol version in force at the time of screening.

Dr Kolawole Isaksen-Balogun, MD, MRCP Independent analytical consultancy
DRAFT-THYROID-C-CE/015 received 12 May 2025

Efficacy outcomes are rated for certainty and harms are not

The draft assigns certainty ratings to the efficacy outcomes and reports harms narratively without ratings. The respondent states that the asymmetry implies harms are less amenable to assessment when they are simply less well measured.

The respondent proposes that harms carry certainty ratings on the same scale, with the reasons for downgrading stated.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted04 Jun 2025

The secretariat accepts this submission. Rating one side of the balance and not the other produces a document that cannot be used to weigh them.

Every reported harm now carries a certainty rating on the same scale as the efficacy outcomes, with the downgrade reasons stated, and discontinuation for adverse events appears in the summary of findings rather than in an annex.

Dr Quentin Enthoven, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-THYROID-C-CE/012 received 13 May 2025

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted in part18 Jun 2025

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Jerome Lavrentiev, PhD (Toxicology) Health-technology assessment agency
DRAFT-THYROID-C-CE/008 received 14 May 2025

Statistical heterogeneity is treated as though it measured clinical heterogeneity

The draft reports a heterogeneity statistic and proceeds to pool where it is low. The respondent states that a low statistic in a small set of trials is uninformative, and that clinical and methodological similarity should be assessed before any statistic is consulted.

The respondent proposes that the decision to pool be justified on clinical grounds first and that the statistic be reported as a description rather than used as a threshold.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseAccepted in part27 May 2025

The secretariat accepts this submission in part. The decision to pool is now made on clinical and methodological grounds and stated as such. The statistic continues to be reported, because readers expect it and its absence would be read as concealment.

The decision to pool is now justified in prose against the population, intervention, comparator and outcome before any statistic is presented, and the heterogeneity statistic is reported with its confidence interval and a note of the number of contributing studies.

Dr Liesbeth Achterberg, MPharm, MRPharmS Academic nephrology unit
DRAFT-THYROID-C-CE/014 received 14 May 2025

Registered trials that never reported are not counted anywhere in the review

The respondent states that the screening flow accounts for records retrieved and excluded but does not record registered trials identified with no posted result, which are neither included nor excluded and simply disappear.

The respondent proposes that they be counted and reported as a category, with the proportion of the registered evidence base they represent.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted16 Jun 2025

The secretariat accepts this submission. A review that cannot say how much of the evidence base is unreported cannot say how much weight its own estimate deserves.

Registered trials without posted results are now identified, counted and reported as a distinct category in the screening flow, with the proportion of registered participants they represent stated in the limitations.

Professor Chukwuemeka Rasmussen-Adeyemi, MD, PhD, FRCP Professor of Endocrinology
DRAFT-THYROID-C-CE/007 received 17 May 2025

The same concept is given three different names in one document

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted29 May 2025

The secretariat accepts this submission. The variation was stylistic and its cost to the reader exceeds any benefit.

A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.